Regulus Therapeutics Inc (NASDAQ:RGLS) Releases Q1 Results: Stock Falls
Biopharmaceutical company Regulus Therapeutics Inc (NASDAQ:RGLS), which is involved on discovering and developing new age medicines that target microRNAs, was in the news yesterday. Trading Data On Thursday, RGLS stock fell 7.57% to $0.2456 with 6.80 million shares, compared to its average volume of 1.99 million shares. The stock moved within a range of $0.1860 – 0.2500 after opening trade at $0.2495. Regulus Therapeutics Reports First Quarter 2022 Financial Results…